Original Article| Volume 23, ISSUE 6, P1571-1576, July 2014

Mild Stroke and Advanced Age Are the Major Reasons for Exclusion from Thrombolysis in Stroke Patients Admitted within 4.5 Hours


      Only 2%-3% of patients with acute ischemic stroke receive thrombolysis. The aim of this study was to identify the reasons for exclusion from thrombolysis in patients admitted within the therapeutic time window.


      Patient data in the hospital stroke registry between January 2012 and September 2013 were retrospectively examined. All cases with a diagnosis of ischemic stroke were screened, and those admitted to the neurology wards within 4.5 hours of symptom onset were analyzed. The reasons for exclusion from thrombolysis were examined. Logistic regression analysis was used to find independent predictors of thrombolysis treatment.


      Of the 1579 cases of ischemic stroke, 234 patients were admitted to the neurology ward within 4.5 hours of symptom onset. A total of 57 patients received thrombolysis. The thrombolysis rate was 3.6% of all ischemic stroke patients. Of the 177 patients who were excluded from thrombolysis, 36.2% (n = 64) had stroke of insufficient severity to warrant thrombolysis, and 24.9% (n = 44) were older than 80 years. Logistic regression analysis showed that the interval between symptom onset and admission (odds ratio 20.24, 95% confidence interval 3.75-109.24) and history of ischemic stroke (odds ratio .11, 95% confidence interval .04-.34) affected the likelihood of thrombolysis.


      Mild stroke and advanced age were the major reasons for exclusion from thrombolysis in patients admitted within 4.5 hours of symptom onset. Patients who were admitted early and those without a history of ischemic stroke were more likely to receive thrombolysis.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • American Heart Association Stroke Council
        Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2013; 44: 870-947
        • European Stroke Organisation (ESO) Executive Committee
        Guidelines for management of ischaemic stroke and transient ischaemic attack 2008.
        Cerebrovasc Dis. 2008; 25: 457-507
        • Kleindorfer D.
        • Lindsell C.J.
        • Brass L.
        • et al.
        National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate.
        Stroke. 2008; 39: 924-928
        • China National Stroke Registry Investigators
        Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR).
        Stroke. 2011; 42: 1658-1664
        • Bambauer K.Z.
        • Johnston S.C.
        • Bambauer D.E.
        • et al.
        Reasons why few patients with acute stroke receive tissue plasminogen activator.
        Arch Neurol. 2006; 63: 661-664
        • Chinese Stroke Collaborative Group
        Chinese guidelines for management of acute ischemic stroke.
        Chinese journal of neurology. 2010; 43: 146-153
        • California Acute Stroke Pilot Registry (CASPR) Investigators
        Prioritizing interventions to improve rates of thrombolysis for ischemic stroke.
        Neurology. 2005; 64: 654-659
        • Willey J.Z.
        • Stillman J.
        • Rivolta J.A.
        • et al.
        Too good to treat? Outcomes in patients not receiving thrombolysis due to mild deficits or rapidly improving symptoms.
        Int J Stroke. 2012; 7: 202-206
        • Smith E.E.
        • Fonarow G.C.
        • Reeves M.J.
        • et al.
        Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke.
        Stroke. 2011; 42: 3110-3115
        • Hao Z.
        • Liu M.
        • Wang D.
        • et al.
        Etiologic subtype predicts outcome in mild stroke: prospective data from a hospital stroke registry.
        BMC Neurol. 2013; 13: 154
        • Rajajee V.
        • Kidwell C.
        • Starkman S.
        • et al.
        Early MRI and outcomes of untreated patients with mild or improving ischemic stroke.
        Neurology. 2006; 67: 980-984
        • Strbian D.
        • Meretoja A.
        • Ahlhelm F.J.
        • et al.
        Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score.
        Neurology. 2012; 78: 427-432
        • IST-3 Collaborative Group
        The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (The Third International Stroke Trial [IST-3]): a randomised controlled trial.
        Lancet. 2012; 379: 2352-2363
        • Rost N.S.
        • Masrur S.
        • Pervez M.A.
        • et al.
        Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke.
        Neurology. 2009; 73: 1957-1962
        • García-Moncó J.C.
        • Pinedo A.
        • Escalza I.
        • et al.
        Analysis of the reasons for exclusion from tPA therapy after early arrival in acute stroke patients.
        Clin Neurol Neurosurg. 2007; 109: 50-53
        • Cocho D.
        • Belvís R.
        • Martí-Fàbregas J.
        • et al.
        Reasons for exclusion from thrombolytic therapy following acute ischemic stroke.
        Neurology. 2005; 64: 719-720
        • Hills N.K.
        • Johnston S.C.
        Why are eligible thrombolysis candidates left untreated?.
        Am J Prev Med. 2006; 31: S210-S216